Age, median years (range)
|
61 (32–86)
|
67 (28–86)
|
0.2
|
57.5 (32–83)
|
64 (47–81)
|
0.07
|
65 (38–86)
|
70 (28–86)
|
0.8
|
Sex, n (%)
| | |
1
| | |
1
| | |
1
|
Male
|
92 (79)
|
23 (79)
| |
49 (82)
|
13 (81)
| |
43 (77)
|
10 (77)
| |
Female
|
24 (21)
|
6 (21)
| |
11 (18)
|
3 (19)
| |
13 (23)
|
3 (23)
| |
ECOG PS, n (%)
| | |
0.5
| | |
0.5
| | |
0.3
|
0
|
84 (73)
|
18 (62)
| |
51 (85)
|
13 (81)
| |
33 (60)
|
5 (38)
| |
1
|
24 (21)
|
8 (28)
| |
8 (13)
|
2 (13)
| |
16 (29)
|
6 (46)
| |
2
|
7 (6)
|
3 (10)
| |
1 (2)
|
1 (6)
| |
6 (11)
|
2 (15)
| |
Smoking status, n (%)
| | |
0.8
| | |
0.9
| | |
0.4
|
Non-smoker
|
35 (31)
|
9 (32)
| |
19 (32)
|
5 (31)
| |
16 (29)
|
4 (33)
| |
Ex-smoker
|
48 (42)
|
13 (46)
| |
29 (49)
|
7 (44)
| |
19 (35)
|
6 (50)
| |
Current smoker
|
31 (27)
|
6 (21)
| |
11 (19)
|
4 (25)
| |
20 (36)
|
2 (17)
| |
Tumour site, n (%)
| | |
0.7
| | |
-
| | |
0.6
|
Lip and oral cavity
|
20 (17)
|
5 (17)
| |
0 (0)
|
0 (0)
| |
20 (36)
|
5 (38)
| |
Nasopharynx
|
8 (7)
|
0 (0)
| |
0 (0)
|
0 (0)
| |
8 (14)
|
0 (0)
| |
Oropharynx
|
60 (52)
|
16 (55)
| |
60 (100)
|
16 (100)
| |
0 (0)
|
0 (0)
| |
Hypopharynx
|
9 (8)
|
3 (10)
| |
0 (0)
|
0 (0)
| |
9 (16)
|
3 (23)
| |
Larynx
|
19 (16)
|
5 (17)
| |
0 (0)
|
0 (0)
| |
19 (34)
|
5 (38)
| |
Tumour stage, n (%)
| | |
0.7
| | |
0.3
| | |
0.8
|
T1
|
31 (27)
|
4 (14)
| |
22 (37)
|
2 (13)
| |
9 (16)
|
2 (15)
| |
T2
|
38 (33)
|
14 (48)
| |
21 (35)
|
8 (50)
| |
17 (30)
|
6 (46)
| |
T3
|
29 (25)
|
7 (24)
| |
11 (18)
|
4 (25)
| |
18 (32)
|
3 (23)
| |
T4
|
18 (16)
|
4 (14)
| |
6 (10)
|
2 (13)
| |
12 (21)
|
2 (15)
| |
Nodal stage, n (%)
| | |
0.5
| | |
0.8
| | |
0.3
|
N0
|
37 (32)
|
7 (24)
| |
10 (17)
|
1 (6)
| |
27 (48)
|
6 (46)
| |
N1
|
26 (22)
|
10 (35)
| |
17 (28)
|
5 (31)
| |
9 (16)
|
5 (38)
| |
N2
|
48 (41)
|
12 (41)
| |
31 (52)
|
10 (63)
| |
17 (30)
|
2 (15)
| |
N3
|
5 (4)
|
0 (0)
| |
2 (3)
|
0 (0)
| |
3 (5)
|
0 (0)
| |
AJCC stage, n (%)
| | |
0.9
| | |
0.9
| | |
0.5
|
I
|
7 (6)
|
2 (7)
| |
4 (7)
|
0 (0)
| |
3 (5)
|
2 (15)
| |
II
|
27 (23)
|
8 (28)
| |
14 (23)
|
4 (25)
| |
13 (23)
|
4 (31)
| |
III
|
59 (51)
|
15 (52)
| |
34 (57)
|
10 (63)
| |
25 (45)
|
5 (38)
| |
IV
|
23 (20)
|
4 (14)
| |
8 (13)
|
2 (13)
| |
15 (27)
|
2 (15)
| |
p16 tumour status, n (%)
| | |
0.8
| | |
0.6
| | |
0.2
|
Negative
|
39 (51)
|
9 (47)
| |
5 (14)
|
2 (25)
| |
34 (85)
|
7 (64)
| |
Positive
|
37 (49)
|
10 (53)
| |
31 (86)
|
6 (75)
| |
6 (15)
|
4 (36)
| |
Treatment, n (%)
| | |
0.8
| | |
0.8
| | |
0.8
|
Radiotherapy
|
14 (12)
|
3 (10)
| |
9 (15)
|
1 (6)
| |
5 (9)
|
2 (15)
| |
Postoperative radiotherapy
|
24 (21)
|
5 (17)
| |
3 (5)
|
0 (0)
| |
21 (38)
|
5 (38)
| |
Chemoradiotherapy
|
68 (59)
|
20 (69)
| |
46 (77)
|
15 (94)
| |
22 (39)
|
5 (38)
| |
Postoperative chemoradiotherapy
|
10 (9)
|
1 (3)
| |
2 (3)
|
0 (0)
| |
8 (14)
|
1 (8)
| |
Neutrophils, median counts (range)
|
4.55 (1.10-11.80)
|
6.80 (3.2-11.90)
|
<0.001
|
4.40 (1.10-9.30)
|
7.85 (3.90-11.90)
|
<0.001
|
5.15 (2.10-2.80)
|
6.50 (3.20-11.80)
|
<0.01
|
Lymphocytes, median counts (range)
|
1.75 (0.50-10.70)
|
1.10 (0.20-1.70)
|
<0.001
|
1.65 (0.50-3.40)
|
1.10 (0.40-1.70)
|
<0.001
|
1.90 (0.60-10.70)
|
1.00 (0.20-1.50)
|
<0.001
|
NLR, median counts (range)
|
2.69 (0.41-5.00)
|
6.71 (5.09-29.75)
|
<0.001
|
2.71 (1.30-4.78)
|
6.41 (5.09-29.75)
|
<0.001
|
2.64 (0.41-5.00)
|
7.00 (5.55-16.00)
|
<0.001
|